Immatics harnesses a suite of technology platforms matched with advanced biologic understanding to identify antigens which are highly specific to cancer cells, thereby delivering true targets: distinct molecular barcodes that identify tumor cells and that are not present on healthy cells. The resulting target resource gives the Immatics team a drug discovery advantage for the company’s own proprietary pipeline and for collaborations with world-leading industry partners.

Immatics expects to grow utilizing the knowledge and experience gained from the partnered programs to improve the development pathways for its proprietary programs.

Our Collaborators


GSK and Immatics enter Strategic Collaboration to develop novel adoptive cell therapies targeting multiple cancers indications, Feb 20, 2020.

Learn more

Bristol-Myers Squibb

Immatics and Celgene, a Bristol-Myers Squibb Company, Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies, Aug 28, 2019.

Learn more


Immatics Enters into a Strategic Partnership with Genmab to Develop Next Generation Bispecific Cancer Immunotherapies, Jul 12, 2018.

Learn more


Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies, Jan 09, 2017.

Learn more

MD Anderson

Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies, Aug 26, 2015.

Learn more


MorphoSys and Immatics Biotechnologies Enter Strategic Alliance in Immuno-oncology, Aug 25, 2015.

Learn more

Contact Us about Partnering Opportunities


Immatics Biotechnologies GmbH
Business Development Group

Machtlfinger Str. 11
81379 München

We use cookies to ensure that we give you the best experience on our website.